北京证券交易所上市公司管理部： 广东驱动力生物科技集团股份有限公司(以下简称"公司")于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》（【2024】第 014 号，以下简称"问询函"），公司董 事会高度重视，立即组织相关部门、人员就问询函中相关问题进行了认真核查并 落实。现对问询函所列问题回复如下： 证券代码：838275 证券简称：驱动力 公告编号：2024-050 广东驱动力生物科技集团股份有限公司 关于对北京证券交易所问询函回复的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 问题一： 补充历史上相关业务的具体开展情况、内容以及金额，并说明公司开展相 关业务的原因及考虑，是否有助于提升公司的核心竞争力和盈利能力，以及公 司对该业务的定位及未来的规划安排； 回复： （一）历史上开展相关业务（造血系列 3 全价配合饲料）的原因及考虑 公司主营业务是研发、生产、销售具有提升动物造血能力的添加剂及添加剂 预混料和全价配合饲 ...

广东驱动力生物科技集团股份有限公司(以下简称"公司")于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》（【2024】第 014 号，以下简称"问询函"），要求公 司就《问询函》相关事项做出书面说明，并在 2024 年 5 月 9 日前将有关说明材 料报送北京证券交易所上市公司管理部并对外披露。 公司收到《问询函》后积极会同相关中介机构对《问询函》中涉及的问题进 行逐项落实与回复。鉴于《问询函》部分问题的回复尚需进一步论证、补充和完 善，为确保回复内容的真实、准确和完整，经向北京证券交易所申请，公司将延 期至 2024 年 5 月 13 日前完成回复工作，并及时履行信息披露义务，敬请广大 投资者谅解。 特此公告。 广东驱动力生物科技集团股份有限公司 董事会 2024 年 5 月 9 日 证券代码：838275 证券简称：驱动力 公告编号：2024-049 广东驱动力生物科技集团股份有限公司 关于延期回复北京证券交易所问询函的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的 ...

1. 补充历史上相关业务的具体开展情况、内容以及金额，并说明公司开展 相关业务的原因及考虑，是否有助于提升公司的核心竞争力和盈利能力，以及 公司对该业务的定位及未来的规划安排； 证券代码：838275 证券简称：驱动力 公告编号：2024-048 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 广东驱动力生物科技集团股份有限公司(以下简称"公司"于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》(问询函【2024】第 014 号(以下简称" 《问询函》")， 现将《问询函》内容公告如下： 广东驱动力生物科技集团股份有限公司（驱动力）董事会、华安证券股份 有限公司、大华会计师事务所（特殊普通合伙）： 2024 年 4 月 29 日，你公司披露《业绩快报修正公告》，对业绩快报中的财 务数据进行修正。营业收入从 14,003.29 万元调整为 9,347.46 万元，调减金额 4,655.83 万元，调减比例为 33.25%。你公司解 ...

关于对广东驱动力生物科技集团股份有限公司 的问询函 合同的主要内容、收入确认政策等，说明前期进行收入确认、审计后 又调减的依据及合理性，是否存在虚增收入的情形； 3.请公司自查相关更正事项是否涉及以前年度财务数据的更正， 并说明公司会计核算、财务制度和内部控制是否存在重大缺陷及拟采 取的改善措施，是否能够保证公司财务数据真实、准确、完整； 2024 年 4 月 29 日，你公司披露《业绩快报修正公告》，对业绩 快报中的财务数据进行修正。营业收入从 14,003.29 万元调整为 9,347.46 万元，调减金额 4,655.83 万元，调减比例为 33.25%。你公司 解释业绩修正主要原因为根据《企业会计准则》的相关规定及要求， 基于谨慎性原则，公司对部分销售合同的收入确认方法采用由总额法 调整为净额法，对部分销售合同的收入进行重新确认。 公司与年报同步披露的《前期会计差错更正公告》显示，公司 对部分业务的收入确认方法采用由总额法调整为净额法，并对 2023 年第三季度、2023 年半年度、2023 年第一季度、2022 年年度及 2021 年度相关财务数据进行了会计差错更正。 请你公司： 1. 补充历史上相 ...

Financial Performance - Net profit attributable to shareholders was CNY 1,007,104.04, down 51.40% year-on-year[12]. - Operating income for the period was CNY 25,990,213.95, a decrease of 5.70% compared to the same period last year[12]. - The company's weighted average return on net assets attributable to shareholders was 0.43%, down from 0.78% in the previous year[10]. - Total operating revenue for Q1 2023 was ¥25,990,213.95, a decrease of 5.7% from ¥27,561,364.26 in Q1 2022[56]. - Net profit for Q1 2023 was ¥978,994.81, down 52.8% from ¥2,072,317.04 in Q1 2022[57]. - The company's operating profit for Q1 2023 was ¥995,316.30, compared to ¥2,232,202.96 in Q1 2022, reflecting a decrease of 55.5%[56]. - The total profit for Q1 2023 was ¥995,316.30, compared to ¥2,224,783.73 in Q1 2022, indicating a decrease of 55.4%[57]. - The company reported investment income of ¥152,837.78 in Q1 2023, down from ¥342,850.02 in Q1 2022, a decline of 55.5%[56]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 251,814,357.83, a decrease of 0.07% compared to the end of the previous year[10]. - The company's asset-liability ratio (consolidated) was 7.05%, down from 7.51% at the end of the previous year[10]. - Total liabilities decreased from CNY 18,927,763.76 to CNY 17,757,123.70, a decline of about 6.2%[50]. - Current liabilities decreased from CNY 18,844,125.25 to CNY 17,673,485.19, a reduction of approximately 6.2%[49]. - The total non-current assets increased to ¥146,311,978.53 from ¥125,815,982.62, showing an increase of approximately 16.3%[48]. - The company's debt investment increased significantly to ¥121,398,282.53 from ¥101,020,670.90, representing a growth of about 20.2%[48]. Cash Flow - Net cash flow from operating activities increased by 307.16% to CNY 2,737,745.79 due to increased product sales and improved collection efforts[14]. - Operating cash inflow for Q1 2023 reached ¥54,665,244.60, a significant increase from ¥29,758,286.00 in Q1 2022, representing an 83.6% growth[61]. - Net cash flow from operating activities for Q1 2023 was ¥2,737,745.79, compared to ¥672,398.83 in Q1 2022, indicating a substantial improvement[62]. - Cash outflow from investment activities in Q1 2023 totaled ¥27,377,925.67, up from ¥23,558,734.64 in Q1 2022, reflecting increased investment efforts[62]. - The net increase in cash and cash equivalents for Q1 2023 was -¥2,613,054.90, contrasting with an increase of ¥24,272,682.04 in Q1 2022, signaling a challenging financial environment[62]. Shareholder Information - The total number of ordinary shareholders was 4,773 at the end of the reporting period[17]. - Liu Jinping and Liu Pingxiang hold 33.2348% and 21.9104% of the shares respectively, together controlling 55.1452% of the voting rights of the company[21]. - The total number of shares held by the top ten shareholders is 122,434,054, accounting for 76.3888% of the total shares[21]. - The largest shareholder, Liu Jinping, has a total of 53,268,016 shares, which is 33.2348% of the total shares[18]. - The company has a total of 70,083,206 shares that are not subject to any restrictions[21]. Compliance and Commitments - The company has committed to avoiding related party transactions and has not engaged in any such transactions during the reporting period[31][35]. - The actual controller has provided a commitment to avoid any competition with the company, ensuring no direct or indirect involvement in similar business activities[29][30]. - The company has committed to strict compliance with regulations regarding social insurance and housing funds, with a plan to increase awareness among employees[33][34]. - The company has established a framework for new commitments in case of non-fulfillment, which will be subject to shareholder approval[43]. - The company will comply with all relevant regulations regarding share reduction and disclosure obligations[37]. Operational Efficiency - The company plans to focus on market expansion and new product development in the upcoming quarters[60]. - Cash inflow from other operating activities in Q1 2023 was ¥11,842,880.77, a significant rise from ¥422,665.75 in Q1 2022, indicating enhanced operational efficiency[61]. - Research and development expenses decreased to ¥706,165.48 in Q1 2023 from ¥885,122.06 in Q1 2022, a reduction of 20.2%[56].

Revenue Performance - The company's total revenue for the first nine months of 2023 was CNY 119.30 million, representing a 12.52% increase compared to CNY 106.03 million in the same period of 2022[4] - The company's revenue for Q3 2023 was CNY 37.26 million, a decrease of 10.86% from CNY 41.80 million in Q3 2022[5] - The company corrected its revenue figures for previous periods, with the revised revenue for the first nine months of 2023 now reported as CNY 72.83 million, a 4.51% increase from CNY 69.68 million in the same period of 2022[6] - Total operating revenue for the first nine months of 2023 reached ¥72,826,122.32, an increase from ¥69,680,718.72 in the same period of 2022, representing a growth of approximately 3.1%[9] Profitability - The net profit attributable to shareholders for the first nine months of 2023 was CNY 5.50 million, a decrease of 62.24% from CNY 14.58 million in the same period of 2022[4] - The net profit attributable to shareholders for Q3 2023 was CNY 2.42 million, down 71.32% from CNY 8.43 million in Q3 2022[5] - Net profit for the first nine months of 2023 was ¥5,414,346.00, down from ¥14,575,213.77 in 2022, indicating a decline of approximately 62.9%[10] - The profit attributable to the parent company's shareholders was ¥5,504,019.06, compared to ¥14,575,213.77 in the previous year, a decrease of around 62.2%[11] - Operating profit for the first nine months of 2023 was ¥5,825,842.70, a decrease from ¥10,912,437.66 in 2022, representing a decline of approximately 46.6%[10] - The company reported a comprehensive income total of ¥5,414,346.00 for 2023, down from ¥14,575,213.77 in 2022, indicating a decrease of about 62.9%[11] Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was CNY 8.63 million, down 76.35% from CNY 36.52 million in the same period of 2022[4] - The net cash flow from operating activities for Q3 2023 was CNY 6.64 million, a decrease of 30.20% from CNY 9.51 million in Q3 2022[5] Earnings Per Share - The basic earnings per share for the first nine months of 2023 was CNY 0.03, a decline of 62.47% compared to CNY 0.09 in the same period of 2022[4] - Basic and diluted earnings per share for 2023 were both ¥0.03, down from ¥0.09 in 2022, reflecting a decline of 66.7%[11] Operating Costs and Income - Total operating costs increased to ¥70,647,120.37 in 2023 from ¥63,995,115.27 in 2022, reflecting a rise of about 10.3%[10] - Other income increased to ¥300,210.70 in 2023 from ¥74,035.92 in 2022, showing a significant rise of about 305.0%[10] - Investment income rose to ¥4,257,151.85 in 2023, compared to ¥2,030,779.45 in 2022, marking an increase of approximately 109.0%[10] Future Outlook - The company plans to continue focusing on new product development and market expansion strategies to improve future performance[3] Apology for Corrections - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[12]

Financial Performance - The company reported a revenue of ¥51,329,621.47, an increase of 9.44% compared to the same period last year[13] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was ¥3,218,083.53, reflecting a growth of 48.98% year-on-year[13] - The company's operating revenue for the reporting period was 82,042,133.18, an increase of 27.73% compared to the previous year[19] - The company reported a net profit of 3,011,597.36, a decrease of 51.01% compared to the previous year, primarily due to a lack of government subsidies received last year[22] - The total revenue for the reporting period was ¥51,329,621.47, reflecting a growth of 9.42% compared to the previous period[42] - The total revenue for the first half of 2023 was CNY 82,042,133.18, an increase from CNY 64,232,221.91 in the same period of 2022, representing a growth of approximately 27.7%[47] - The net profit for the first half of 2023 was CNY 1,059,673.99, a significant decrease from a net loss of CNY 682,378.97 in the same period of 2022[46] Profitability Metrics - The gross profit margin decreased to 24.72% from 27.87% in the previous year[5] - The gross profit margin decreased to 15.46%, down 4.89 percentage points year-on-year, attributed to changes in product sales structure[19] - The gross profit margin for self-produced products decreased by 5.39 percentage points to 14.87%[32] - The gross profit margin for the overall business was 15.46%, down 4.89 percentage points from the previous year[38] - The operating profit was 3,090,234.36, down 18.01% year-on-year, influenced by a downturn in the downstream livestock industry[21] Operating Efficiency - The net cash flow from operating activities was ¥1,999,325.39, down 92.60% from ¥27,011,084.65 in the previous year[9] - The accounts receivable turnover rate improved to 1.99 from 1.19 year-on-year[9] - The inventory turnover rate increased to 3.47 from 2.58 in the previous year[9] - The credit impairment loss increased by 429.46% to -806,471.23, due to an increase in accounts receivable and the need to provision for bad debts[19] Revenue Sources - Revenue from blood products is $48,984,385.33, compared to $36,728,640.76 in the previous period, reflecting a significant increase of approximately 33.3%[57] - Revenue from stress-resistant and appetite-inducing products decreased to $913,841.93 from $2,133,811.87, a decline of about 57.1%[57] - Revenue from technical services decreased to $116,428.00 from $1,224,145.00, a decline of about 90.5%[57] - Other business revenue increased by 21.80% to ¥93,209.02, up from ¥76,529.15[31] Strategic Initiatives - The company launched cost-reduction products for livestock farmers in response to market pressures[12] - New departments were established, including ruminant, e-commerce, aquaculture, and regional divisions, to enhance market expansion[12] - The company aims to expand its product matrix to include aquaculture and pet sectors, leveraging its patented blood product technology[15] - The company plans to expand its market presence and invest in new product development to drive future growth[46] - The company has identified strategic opportunities for mergers and acquisitions to enhance its competitive position in the market[46] Other Financial Metrics - Other income increased significantly by 725.41% to 300,210.70, mainly due to government rewards received during the period[21] - Investment income rose to 2,482,029.52, a 145.04% increase, driven by higher returns from associated companies and increased interest from large time deposits[21] - Research and development expenses for the first half of 2023 were CNY 2,137,582.81, slightly down from CNY 2,293,360.29 in the first half of 2022, reflecting a decrease of about 6.8%[47] - The total assets of the company were reported at CNY 81,864,563.44, with net assets amounting to CNY 10,739,638.46[46] Market Position - The company maintains a leading position in the industry, supported by strong brand recognition and technological advancements[15] - The sales structure of the new product series accounted for 75.17% of total sales, contributing to the decline in gross margin[38] - Revenue from the Northeast region increased by 215.13% to ¥1,709,073.60, while the gross margin was 49.47%[41] Miscellaneous - The company expressed apologies for any inconvenience caused by the corrections made to the financial report[58] - The company has not disclosed any new product launches or technological advancements during this reporting period[58] - There are no updates on market expansion or mergers and acquisitions mentioned in the conference call[58]

Financial Performance - The company's revenue for 2022 was corrected to ¥97,072.53 million, a decrease of 28.62% compared to 2021[6]. - The net profit attributable to shareholders for 2022 was corrected to ¥17,399.34 million, reflecting a decrease of 56.52% year-over-year[10]. - The gross profit margin for 2022 was adjusted to 30.56%, down from 43.98% in 2021[6]. - The basic earnings per share for 2022 was corrected to ¥0.11, a decline of 56% compared to ¥0.25 in 2021[5]. - The overall operating profit margin was reported at 12.4%, down from 31.3% in the previous year[19]. - The operating profit for the reporting period was 19.19 million, a decrease of 55.43% compared to 2021, primarily due to a smaller increase in main business income compared to the increase in operating costs[24]. - The net profit for the reporting period was 17.38 million, a decrease of 56.56% compared to 2021, influenced by multiple factors[24]. - The company reported a net profit margin impacted by increased R&D expenses and operational costs[58]. - Total operating revenue for 2022 was 97,072,539, a decrease of 28.5% compared to 135,985,501 in 2021[60]. - Net profit for 2022 was 17,382,063, representing a decline of 56.6% from 40,017,018 in 2021[62]. Cash Flow - The net cash flow from operating activities for 2022 was ¥54,469.48 million, an increase of 112% from ¥25,658.46 million in 2021[8]. - The net cash flow from operating activities was 54,469.5 million, an increase of 112.29% compared to the previous year, driven by higher sales cash ratios[35]. - The net cash flow from investing activities was -21,838.7 million, an increase of 68.51% year-on-year, mainly due to reduced fixed asset investments[35]. - The net cash flow from financing activities was -49,349.2 million, a decrease of 245.05% compared to the previous year, attributed to the absence of external financing in 2022[35]. Operating Costs and Expenses - Operating costs amounted to 67,410,728 yuan, reflecting a decrease of 11.51% from 76,174,676 yuan in the previous year[19]. - Sales expenses were 10,897,595 yuan, a reduction of 15.18% compared to 12,847,418 yuan in the previous year[19]. - The operating cost for the reporting period was 67.18 million, a decrease of 11.58% compared to 2021, mainly due to reduced sales volume of blood products[25]. - Research and development expenses increased by 19.23% to 4,749,646 yuan from 3,983,697 yuan in the previous year[19]. Revenue Sources - The revenue from hematopoietic products was 84,102.3 million, a decrease of 8.55% compared to the same period in 2021[32]. - The revenue from other products was 12,970.2 million, a decrease of 70.54% year-on-year, primarily due to a reduction in various feed materials and technical service fees[31]. - Revenue from blood products was 79,906,522.33, down from 89,420,301.90 in the previous period[64]. - Revenue from stress-resistant and appetite-inducing products was 4,195,808.87, an increase from 2,543,664.50 in the previous period[64]. - Revenue from concentrated feed and additives was 8,702,552.93, down from 30,976,376.37 in the previous period[64]. Audit and Compliance - The company identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue recognition timing[48]. - The company has implemented significant audit procedures to evaluate the effectiveness of internal controls related to revenue recognition[49]. - The company's revenue recognition policy aligns with accounting standards, ensuring compliance[55]. - The company’s management has been proactive in addressing potential risks associated with revenue recognition practices[48]. Subsidiaries and Investments - The company has four wholly-owned subsidiaries, one controlling subsidiary, and one associated company as of December 31, 2022[42]. - Guangzhou Sanhang Biotechnology Co., Ltd. generated revenue of 3.76 million yuan and a net profit of 0.55 million yuan during the reporting period[42]. - Guangzhou Sanhang Feed Co., Ltd. achieved revenue of 11.83 million yuan and a net profit of 0.87 million yuan[45]. - Guangdong Sanhang Biotechnology Co., Ltd. reported revenue of 37.09 million yuan and a net profit of 0.31 million yuan[45]. - Guangzhou Saitao Flower Biotechnology Co., Ltd. generated revenue of 2.56 million yuan and a net profit of 1.37 million yuan[45]. - Guangdong Sanhang Blood Feed Co., Ltd. reported a net loss of 0.035 million yuan during the reporting period[43]. - Guangdong Xinnandu Feed Technology Co., Ltd. achieved revenue of 55.96 million yuan and a net profit of 5.46 million yuan[45]. Management Commentary - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[65]. - The company plans to expand its market presence and enhance product offerings through new technology development and strategic partnerships[30].

证券代码：838275 证券简称：驱动力 公告编号：2024-018 广东驱动力生物科技集团股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 本公司于 2020 年 12 月 25 日收到中国证券监督管理委员会下发的《关于核 准广东驱动力生物科技股份有限公司向不特定合格投资者公开发行股票的批复》 （证监许可）【2020】3625 号），核准公司向不特定合格投资者公开发行不超过 1,200 万股新股（含行使超额配售选择权所发新股）。公司本次发行的价格为 5.00 元/股，发行股数 1,200 万股（含行使超额配售选择权所发行的股份），实际募集 资金 60,000,000.00 元（超额配售选择权行使后），扣除发行费用人民币 11,800,066.04 元（不含税）后，募集资金净额为人民币 48,199,933.96 元。截 止 2021 年 2 月 24 日，上述募集资金已全部到账，经大华会计师事务所（特殊普 通合伙）验资，并由其出具 ...

2023 年度独立董事述职报告（李平） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：838275 证券简称：驱动力 公告编号：2024-026 广东驱动力生物科技集团股份有限公司 本人李平自 2023 年 11 月 16 日起担任广东驱动力生物科技集团股份有限公 司(以下简称"公司") 的独立董事，在任职期间严格按照《公司法》《证券法》 《上市公司独立董事管理办法》《北京证券交易所股票上市规则（试行）》《北京 证券交易所上市公司持续监管指引第 1 号——独立董事》、等法律法规的规定以 及《公司章程》和《独立董事工作制度》的要求，谨慎、认真、勤勉、独立地履 行职责，持续关注公司规范运作、重大生产经营活动、财务状况等，积极出席 2023 年度的相关会议，认真审议各项议案，对重大事项发表了独立意见，维护了公司 整体利益和全体股东尤其是中小股东的合法权益。 现就 2023 年度任职期间内履行职责情况汇报如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 ...